Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R D Knight
Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression
Annals of Hematology
Medicine
Hematology
Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Missing HLA C Group 1 Ligand in Patients With AML and MDS Is Associated With Reduced Risk of Relapse and Better Survival After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning
American Journal of Hematology
Hematology
Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results
American Journal of Hematology
Hematology
Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide
Haematologica
Hematology
Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
Frontiers in Pharmacology
Pharmacology
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy
Mediterranean Journal of Hematology and Infectious Diseases
Infectious Diseases
Hematology
